Chemotherapy-free approaches to newly-diagnosed acute promyelocytic leukemia: is oral-arsenic trioxide/all-trans retinoic acid/ascorbic acid the answer?

References

• Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 2009;114(25):5126–5135. doi:10.1182/blood-2009-07-216457
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood, 100(13), 4298–4302 (2002).
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Haferlach C, Saussele S, et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia. 2009;23(12):2248–2258. doi: 10.1038/leu.2009.183
   PubMedGoogle Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116(17):3171–3179. doi: 10.1182/blood-2010-03-276196
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Chevret S, De Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL group experience. J Clin Oncol. 2009;27(16):2668–2676. doi: 10.1200/JCO.2008.18.4119
   PubMed Web of Science ®Google Scholar
• Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009;106(9):3342–3347. doi: 10.1073/pnas.0813280106
   PubMed Web of Science ®Google Scholar
• Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120(8):1570–1580; quiz 1752. doi: 10.1182/blood-2012-02-410746
   PubMedGoogle Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121. doi: 10.1056/NEJMoa1300874
   PubMed Web of Science ®Google Scholar
• Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129(10):1275–1283. doi: 10.1182/blood-2016-09-736686
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–1305. doi: 10.1016/S1470-2045(15)00193-X
   PubMed Web of Science ®Google Scholar
• Kumana CR, Mak R, Kwong YL, et al. Resurrection of oral arsenic trioxide for treating acute promyelocytic leukaemia: a historical account from bedside to bench to bedside. Front Oncol. 2020;10:1294. doi:10.3389/fonc.2020.01294
   PubMedGoogle Scholar
• Au WY, Kumana CR, Kou M, et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood. 2003;102(1):407–408. doi: 10.1182/blood-2003-01-0298
   PubMed Web of Science ®Google Scholar
• Au WY, Li CK, Lee V, et al. Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients. Pediatr Blood Cancer. 2012;58(4):630–632. doi: 10.1002/pbc.23306
   PubMed Web of Science ®Google Scholar
• Au WY, Kumana CR, Lee HK et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood, 118(25), 6535–6543 (2011).
   PubMed Web of Science ®Google Scholar
• Gill H, Kumana CR, Yim R, et al. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: a 5-year prospective study. Cancer. 2019;125(17):3001–3012. doi: 10.1002/cncr.32180
   PubMed Web of Science ®Google Scholar
• Gill HS, Yim R, Kumana CR, et al. Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators. Cancer, 126(14), 3244–3254 10.1002/cncr.32937(2020).. 2020
   PubMedGoogle Scholar
• Kwong YL, Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood, 89(9), 3487–3488 (1997).
   PubMed Web of Science ®Google Scholar
• Au WY. A biography of arsenic and medicine in Hong Kong and China. Hong Kong Med J, 17(6), 507–513 (2011).
   PubMedGoogle Scholar
• Kumana CR, Au WY, Lee NS et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol, 58(8), 521–526 (2002).
   PubMed Web of Science ®Google Scholar
• Siu CW, Au WY, Yung C, et al. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood. 2006;108(1):103–106. doi: 10.1182/blood-2006-01-0054
   PubMed Web of Science ®Google Scholar
• Hai JJ, Gill H, Tse HF, et al. Torsade de pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure. Ann Hematol. 2015;94(3):501–503. doi:10.1007/s00277-014-2174-1
   PubMedGoogle Scholar
• Au WY, Kwong YL. Arsenic trioxide: safety issues and their management. Acta Pharmacol Sin. 2008;29(3):296–304. doi:10.1111/j.1745-7254.2008.00771.x
   PubMed Web of Science ®Google Scholar
• Au WY, Cheung GT, Yuen TW, Kumana CR, Kwong YL. Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide. Arch Intern Med, 165(9), 1067–1068 (2005).
   PubMedGoogle Scholar
• Au WY, Fong BM, Tam S, et al. Feasibility of oral arsenic trioxide treatment for acute promyelocytic leukemia during hemodialysis. Ann Hematol. 2013;92(3):417–418. doi:10.1007/s00277-012-1576-1
   PubMedGoogle Scholar
• Au WY, Tam S, Fong BM, et al. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood. 2008;112(9):3587–3590. doi:10.1182/blood-2008-06-161000
   PubMed Web of Science ®Google Scholar
• Au WY, Tam S, Kwong YL. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment. Leuk Res. 2008;32(2):357–358. doi:10.1016/j.leukres.2007.06.005
   PubMed Web of Science ®Google Scholar
• Gill H, Yim R, Lee HKK, et al. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: a 15-year prospective study. Cancer. 2018;124(11):2316–2326. doi: 10.1002/cncr.31327
   PubMed Web of Science ®Google Scholar
• Dai J, Weinberg RS, Waxman S, et al. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1999;93(1):268–277. doi:10.1182/blood.V93.1.268
   PubMed Web of Science ®Google Scholar
• Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood, 98(3), 805–813 (2001).
   PubMedGoogle Scholar
• Au WY, Kwong YL. Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge. J Am Acad Dermatol. 2005;53(5):890–892. doi:10.1016/j.jaad.2005.07.030
   PubMed Web of Science ®Google Scholar
• Gill H, Raghupathy R, Ni M, et al.. Epidemiology and outcomes of acute promyelocytic leukaemia in the era of all-trans retinoic acid (ATRA) chemotherapy and arsenic trioxide plus ATRA: a retrospective analysis. The Lancet Oncology. 2022;23:S11. doi: 10.1016/S1470-2045(22)00410-7
   PubMedGoogle Scholar
• Gill H, Raghupathy R, Lee CY et al. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021. BMC Cancer, 23(1), 141 (2023).
   PubMedGoogle Scholar
• Gill H, Yung Y, Chu HT, et al. Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study. Blood Adv. 2021;5(14):2829–2838. doi: 10.1182/bloodadvances.2021004789
   PubMedGoogle Scholar
• Norsworthy KJ, Avagyan A, Bird ST, et al. Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis. Leukemia. 2020;34(11):3082–3084. doi: 10.1038/s41375-020-0905-y
   PubMedGoogle Scholar
• Singh AP, Goel RK, Kaur T. Mechanisms pertaining to arsenic toxicity. Toxicol Int, 18(2), 87–93 (2011).
   PubMedGoogle Scholar
• Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469–3473. doi: 10.1182/blood-2005-10-4006
   PubMed Web of Science ®Google Scholar
• Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27(4):504–510. doi: 10.1200/JCO.2008.18.6130
   PubMed Web of Science ®Google Scholar
• Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: north american leukemia intergroup study C9710. Blood. 2010;116(19):3751–3757. doi: 10.1182/blood-2010-02-269621
   PubMed Web of Science ®Google Scholar
• Sanz MA, Martin G, Gonzalez M et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood, 103(4), 1237–1243 (2004).
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Avvisati G, Cicconi L et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol, 35(6), 605–612 (2017).
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou GB, Liu P, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A. 2008;105(12):4826–4831. doi: 10.1073/pnas.0712365105
   PubMed Web of Science ®Google Scholar
• Wu J, Shao Y, Liu J, Chen G, Ho PC. The medicinal use of realgar (As(4)S(4)) and its recent development as an anticancer agent. J Ethnopharmacol, 135(3), 595–602 (2011).
   PubMed Web of Science ®Google Scholar
• Zhu HH, Wu DP, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013;31(33):4215–4221. doi: 10.1200/JCO.2013.48.8312
   PubMed Web of Science ®Google Scholar
• Gill H, Yim R, Chin L, et al. An entirely oral regimen of oral-arsenic Trioxide/All-Trans Retinoic Acid/Ascorbic Acid in newly-diagnosed acute promyelocytic leukaemia (APL): updated results of an ongoing multicentre trial. Blood. 2023;142(Supplement 1):157. doi: 10.1182/blood-2023-179644
   Google Scholar
• Gill H, Raghupathy R, Hou H-A, et al.. P493: ORAL-ATO/ATRA/ASCORBIC ACID (AAA)-BASED INDUCTION OR MAINTENANCE OF FIRST COMPLETE REMISSION IMPROVED OUTCOMES IN NEWLY DIAGNOSED APL: A MULTICENTRE ANALYSIS OF THE APL ASIAN CONSORTIUM (APLAC). HemaSphere. 2023;7(S3):e6159196. doi: 10.1097/01.HS9.0000968880.61591.96
   Google Scholar
• Sanz MA, Montesinos P, Rayon C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115(25):5137–5146. doi: 10.1182/blood-2010-01-266007
   PubMed Web of Science ®Google Scholar
• Jacomo RH, Melo RA, Souto FR, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007;92(10):1431–1432. doi: 10.3324/haematol.10874
   PubMed Web of Science ®Google Scholar
• Serefhanoglu S, Buyukasik Y, Goker H et al. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy. Leuk Res, 34(12), e317–319 (2010).
   PubMedGoogle Scholar
• Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the swedish adult acute leukemia registry. Leukemia. 2011;25(7):1128–1134. doi: 10.1038/leu.2011.78
   PubMed Web of Science ®Google Scholar
• Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248–1254. doi: 10.1182/blood-2011-04-346437
   PubMed Web of Science ®Google Scholar
• Chen Y, Kantarjian H, Wang H, et al. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Cancer. 2012;118(23):5811–5818. doi:10.1002/cncr.27623
   PubMed Web of Science ®Google Scholar
• Jeddi R, Ghedira H, Ben Amor R, et al. Treatment of acute promyelocytic leukemia with AIDA based regimen. Update of a Tunisian single center study. Mediterr J Hematol Infect Dis. 2011;3(1):e2011033. doi: 10.4084/mjhid.2011.033
   PubMedGoogle Scholar
• McClellan JS, Kohrt HE, Coutre S, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97(1):133–136. doi: 10.3324/haematol.2011.046490
   PubMed Web of Science ®Google Scholar
• Pagoni M, Garofalaki M, Panitsas F, et al. Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic acid era. Mediterr J Hematol Infect Dis. 2011;3(1):e2011053. doi: 10.4084/mjhid.2011.053
   PubMedGoogle Scholar
• Imagawa J, Harada Y, Shimomura T, et al. High early death rate in elderly patients with acute promyelocytic leukemia treated with all-trans retinoic acid combined chemotherapy. Int J Hematol. 2013;98(2):264–266. doi:10.1007/s12185-013-1390-0
   PubMedGoogle Scholar
• Paulson K, Serebrin A, Lambert P, et al. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol. 2014;166(5):660–666. doi: 10.1111/bjh.12931
   PubMed Web of Science ®Google Scholar
• Karim F, Shaikh U, Adil SN, et al. Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre. Singapore Med J. 2014;55(8):443–447. doi:10.11622/smedj.2014105
   PubMed Web of Science ®Google Scholar
• Bajpai J, Sharma A, Kumar L, et al. Acute promyelocytic leukemia: an experience from a tertiary care centre in north India. Indian J Cancer. 2011;48(3):316–322. doi: 10.4103/0019-509X.84938
   PubMed Web of Science ®Google Scholar
• Rahme R, Thomas X, Recher C, et al. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia. 2014;28(12):2422–2424. doi: 10.1038/leu.2014.240
   PubMed Web of Science ®Google Scholar
• Guru Murthy GS, Szabo A, Michaelis L, et al. Improving outcomes of acute promyelocytic leukemia in the Current era: analysis of the SEER database. J Natl Compr Canc Netw. 2020;18(2):169–175. doi: 10.6004/jnccn.2019.7351
   PubMed Web of Science ®Google Scholar
• Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630–1643. doi: 10.1182/blood-2019-01-894980
   PubMed Web of Science ®Google Scholar
• Kayser S, Rahme R, Martinez-Cuadron D et al. Outcome of older (>/=70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. Leukemia, 34(9), 2333–2341 (2020).
   PubMed Web of Science ®Google Scholar
• Gurnari C, Breccia M, Di Giuliano F, et al. Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters. Br J Haematol. 2021;193(1):129–132. doi: 10.1111/bjh.17018
   PubMed Web of Science ®Google Scholar
• Altman JK, Rademaker A, Cull E, et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res. 2013;37(9):1004–1009. doi: 10.1016/j.leukres.2013.05.007
   PubMed Web of Science ®Google Scholar
• Kwaan HC, Weiss I, Tallman MS. The role of abnormal hemostasis and fibrinolysis in morbidity and mortality of acute promyelocytic leukemia. Semin Thromb Hemost. 2019;45(6):612–621. doi:10.1055/s-0039-1693478
   PubMed Web of Science ®Google Scholar
• Kwaan HC, Cull EH. The coagulopathy in acute promyelocytic leukaemia–what have we learned in the past twenty years. Best Pract Res Clin Haematol. 2014;27(1):11–18. doi:10.1016/j.beha.2014.04.005
   PubMedGoogle Scholar